[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568534":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":49,"collaborators":52,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Children with obesity",null,"Children with obesity followed within the pediatric endocrine and diabetes unit of the University Hospitals of Geneva, Switzerland. The investigators will do prospective measures in 50 children aged 12 to 15 years, at the time of a planned oral glucose tolerance test and again, 2 years later.",[13],"Other: Measurement of biomarker",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Measurement of biomarker","Measurement of blood levels of 1,5-anhydroglucitol",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Philippe Klee","CONTACT","+41 79 55 33 476","philippe.klee@unige.ch",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},"Pierre Maechler","pierre.maechler@unige.ch",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University Hospital of Geneva","RECRUITING","Geneva","Canton of Geneva","1211","Switzerland","CH",{"type":38,"coordinates":39},"Point",[40,41],6.14569,46.20222,{"lat":41,"lon":40},[44,47],{"name":45,"role":22,"phone":23,"phoneExt":10,"email":46},"Philippe Klee, MD-PhD","philippe.klee@hcuge.ch",{"name":45,"role":48,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":45,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Principal Investigator",[53],{"name":54,"class":6},"University of Geneva, Switzerland","100568534","beta-cell---liver-interactions-in-situations-of-modified-beta-cell-function-100568534",false,"NCT06682481","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children","Inclusion Criteria:\n\n* Children aged 12 to 16 years\n* Obesity. Defined as a body-mass index above the 97th percentile.\n* Ability to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.\n* Patients with known liver disease (other than NAFLD)\n* Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.\n* Patients treated with a drug known to affect liver function","ALL","12 Years","16 Years",{"count":66,"type":67},50,"ESTIMATED","OBSERVATIONAL","The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.",[71,72],"Obesity, Childhood","Type 2 Diabetes Mellitus in Obese","2026-05-14",{"date":75,"type":76},"2026-05-18","ACTUAL",{"date":78,"type":76},"2024-11-22",{"date":80,"type":67},"2028-12-31",{"name":45,"class":6},1]